Clinical Reasoning in the Use of Long-acting Aripiprazole in Psychosis in Bilateral Nephrectomy on Hemodialysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Psychiatric disorders are common in patients on hemodialysis. To the best of our knowledge there are no reported cases of psychosis developing in hemodialysis patients in the context of nephrectomy, and there is limited data on the use of long-acting antipsychotics in hemodialysis, which are generally not recommended in chronic kidney disease. We present the case of a 40-year-old lady with bilateral nephrectomy receiving hemodialysis who developed psychosis that resulted in her refusing to continue hemodialysis and was irregularly compliant with oral antipsychotics, necessitating the use of a long-acting injection. We report on the approach to clinical reasoning in the choice of aripiprazole and the need for a long-acting injection. Based on its pharmacological and pharmacokinetic properties oral aripiprazole 20 mg was commenced and after establishing tolerability and response, the patient was switched to long-acting aripiprazole 400 mg monthly achieving full remission of psychotic symptoms after 6 months with maintained improvement after 12 months. Based on its properties, aripiprazole may be a reasonable option in the treatment of psychosis in patients on hemodialysis with nephrectomy and can be considered even as a long-acting injection in these patients.
Abstract
Psychiatric disorders are common in patients on hemodialysis. To the best of our knowledge there are no reported cases of psychosis developing in hemodialysis patients in the context of nephrectomy, and there is limited data on the use of long-acting antipsychotics in hemodialysis, which are generally not recommended in chronic kidney disease. We present the case of a 40-year-old lady with bilateral nephrectomy receiving hemodialysis who developed psychosis that resulted in her refusing to continue hemodialysis and was irregularly compliant with oral antipsychotics, necessitating the use of a long-acting injection. We report on the approach to clinical reasoning in the choice of aripiprazole and the need for a long-acting injection. Based on its pharmacological and pharmacokinetic properties oral aripiprazole 20 mg was commenced and after establishing tolerability and response, the patient was switched to long-acting aripiprazole 400 mg monthly achieving full remission of psychotic symptoms after 6 months with maintained improvement after 12 months. Based on its properties, aripiprazole may be a reasonable option in the treatment of psychosis in patients on hemodialysis with nephrectomy and can be considered even as a long-acting injection in these patients.
참고문헌 (27)
- Chan L, "Textbook of medical psychiatry", pp.319~ (2020), American Psychiatric Association Publishing
- Cukor D, "Depression and anxiety in urban hemodialysis patients", Clin J Am Soc Nephrol, 2, pp.484~490 (2007)
- Scott IA, "Going digital : a narrative overview of the effects, quality and utility of mobile apps in chronic disease self-management", Aust Health Rev, 44, pp.62~82 (2020)
- Acosta-Ochoa I, "Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function", J Clin Med, 8, pp.1323~ (2019)
- Chapter 1, "Definition and classification of CKD", Kidney Int Suppl(2011), 3, pp.19~62 (2013)
- Jin DC, "Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985-2015", Kidney Res Clin Pract, 34, pp.132~139 (2015)
- Eyler RF, "Psychotherapeutic agents in end-stage renal disease", Semin Dial, 28, pp.417~426 (2015)
- Fukunishi I, "Psychiatric disorders among patients undergoing hemodialysis therapy", Nephron, 91, pp.344~347 (2002)
- Cohen SD, "Anxiety in patients treated with hemodialysis", Clin J Am Soc Nephrol, 11, pp.2250~2255 (2016)
- Cukor D, "Anxiety disorders in adults treated by hemodialysis : a single-center study", Am J Kidney Dis, 52, pp.128~136 (2008)
- Kimmel PL, "Psychiatric illness and mortality in hospitalized ESKD dialysis patients", Clin J Am Soc Nephrol, 14, pp.1363~1371 (2019)
- Sutar R, "Antipsychotics and hemodialysis : a systematic review", Asian J Psychiatr, 55, pp.102484~ (2021)
- Taylor DM, "The Maudsley prescribing guidelines in psychiatry", pp.735~ (2021), Wiley-Blackwell
- Ward S, "When to adjust the dosing of psychotropics in patients with renal impairment", Curr Psychiatr, 15, pp.60~66 (2016)
- Johnson CA, "2010 Dialysis of drugs", pp.2~56 (2010), CKD Insights, LLC
- De Donatis D, "Serum aripiprazole concentrations prehemodialysis and posthemodialysis in a schizophrenic patient with chronic renal failure : a case report", J Clin Psychopharmacol, 40, pp.200~202 (2020)
- "Aripiprazole therapy and CYP2D6 genotype" (2021)[URL]
- Uzun S, "Aripiprazole : an overview of a novel antipsychotic", Psychiatr Danub, 17, pp.67~75 (2005)
- Silki, "Enhancement of in vivo efficacy and oral bioavailability of aripiprazole with solid lipid nanoparticles", AAPS PharmSciTech, 19, pp.1264~1273 (2018)
- Mihajlovic T, "Improvement of aripiprazole solubility by complexation with(2-hydroxy)propyl-β-cyclodextrin using spray drying technique", AAPS PharmSciTech, 13, pp.623~631 (2012)
- McKim W, "Drugs and behavior: an introduction to behavioral pharmacology" (2007), Pearson
- Javaid JI, "Clinical pharmacokinetics of antipsychotics", J Clin Pharmacol, 34, pp.286~295 (1994)
- Oh J, "Effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social performance of patients with schizophrenia", Clin Psychopharmacol Neurosci, 21, pp.126~134 (2023)
- Kim SW, "Effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia", Clin Psychopharmacol Neurosci, 21, pp.57~67 (2023)
- Carpiniello B, "Delusional infestation in a patient with renal failure, metabolic syndrome, and chronic cerebrovascular disease treated with aripiprazole : a case report", Case Rep Med, 2011, pp.103652~ (2011)
- Tzeng NS, "Delusional parasitosis in a patient with brain atrophy and renal failure treated with aripiprazole : case report", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.1148~1149 (2010)
- Duarte C, "Delusional parasitosis associated with dialysis treated with aripiprazole", Acta Med Port, 24, pp.457~462 (2011)